Drug-induced pulmonary arterial hypertension: A recent outbreak

European Respiratory Review

Volumn 22, Issue 129, 2013, Pages 244-250

  Montani, David ^a,b,c   Seferian, Andrei ^a,b,c   Savale, Laurent ^a,b,c   Simonneau, Gérald ^a,b,c   Humbert, Marc ^a,b,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b BICÊTRE HOSPITAL   (France)

^c CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMINOREX; AMPHETAMINE DERIVATIVE; BENFLUOREX; COCAINE; DASATINIB; DEXFENFLURAMINE; FENFLURAMINE; MAZINDOL; METHAMPHETAMINE; PHENTERMINE; PHENYLPROPANOLAMINE; RECOMBINANT BETA INTERFERON; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRYPTOPHAN;

ARTERY MUSCLE; ASTHMA; BONE MARROW SUPPRESSION; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CARDIOMYOPATHY; CHRONIC MYELOID LEUKEMIA; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; DRUG EXPOSURE; DRUG WITHDRAWAL; ENDOTHELIAL DYSFUNCTION; FLU LIKE SYNDROME; HEART ARRHYTHMIA; HEMATOLOGIC MALIGNANCY; HEPATITIS; HEPATITIS C; HUMAN; KIDNEY CANCER; KIDNEY FAILURE; LIVER FAILURE; LUNG ARTERY; LUNG BLOOD VESSEL; LUNG INFILTRATE; LUNG VASCULAR RESISTANCE; MEDICAL RESEARCH; MULTIPLE SCLEROSIS; NARCOLEPSY; OBESITY; PLEURA EFFUSION; POLYNEUROPATHY; PULMONARY HYPERTENSION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SARCOIDOSIS; SEROTONIN BLOOD LEVEL; SKIN CANCER; SMOOTH MUSCLE FIBER;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ARTERIAL PRESSURE; DISEASE OUTBREAKS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; HYPERTENSION, PULMONARY; PULMONARY ARTERY; RISK FACTORS;

EID: 84883366292     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00003313     Document Type: Review

References (48)

1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-117.
2. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1, S43-S54
3. Gurtner HP. Chronische pulmonale Hypertonie vaskularen Ursprungs, plexogene pulmonale Arteriopathie und der Appetitzugler Aminorex: Nachlese zu einer Epidemie [Chronic pulmonary hypertension of vascular aetiology, plexogenic pulmonary arteriopathy and the appetite depressant Aminorex: lessons from an epidemic]. Schweiz Med Wochenschr 1985; 115: 818-827.
4. Gurtner HP. Aminorex and pulmonary hypertension: a review. Cor Vasa 1985; 27: 160-171.
5. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219-1263.
6. Kay JM, Smith P, Heath D. Aminorex and the pulmonary circulation. Thorax 1971; 26: 262-270.
7. Simonneau G, Fartoukh M, Sitbon O, et al. Primary pulmonary hypertension associated with the use of fenfluramine derivatives. Chest 1998; 114: Suppl. 3, 195S-199S
8. Eddahibi S, Adnot S. Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: lessons for the future in pathogenesis. Respir Res 2002; 3: 9.
9. Eddahibi S, Raffestin B, Hamon M, et al. Is the serotonin transporter involved in the pathogenesis of pulmonary hypertension? J Lab Clin Med 2002; 139: 194-201.
10. Eddahibi S, Humbert M, Fadel E, et al. Hyperplasia of pulmonary artery smooth muscle cells is causally related to overexpression of the serotonin transporter in primary pulmonary hypertension. Chest 2002; 121: Suppl. 3, 97S-98S.
11. Herve P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99: 249-254.
12. Loogen F, Worth H, Schwan G, et al. Long-term follow-up of pulmonary hypertension in patients with and without anorectic drug intake. Cor Vasa 1985; 27: 111-124.
13. Douglas JG, Munro JF, Kitchin AH, et al. Pulmonary hypertension and fenfluramine. Br Heart J (Clin Res Ed) 1981; 283: 881-883.
14. Brenot F, Herve P, Petitpretz P, et al. Primary pulmonary hypertension and fenfluramine use. Br Heart J 1993; 70: 537-541.
15. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 335: 609-616.
16. Souza R, Humbert M, Sztrymf B, et al. Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. Eur Respir J 2008; 31: 343-348.
17. Boutet K, Frachon I, Jobic Y, et al. Fenfluramine-like cardiovascular side-effects of benfluorex. Eur Respir J 2009; 33: 684-688.
18. Frachon I, Etienne Y, Jobic Y, et al. Benfluorex and unexplained valvular heart disease: a case-control study. PLoS One 2010; 5: e10128.
19. Savale L, Chaumais MC, Cottin V, et al. Pulmonary hypertension associated with benfluorex exposure. Eur Respir J 2012; 40: 1164-1172.
20. van Wolferen SA, Vonk Noordegraaf A, Boonstra A, et al. Pulmonale arteriele hypertensie door amfetaminen gebruikt als drugs of doping [Pulmonary arterial hypertension due to the use of amphetamines as drugs or doping]. Ned Tijdschr Geneeskd 2005; 149: 1283-1288.
21. Collazos J, Marti{dotless}́nez E, Fernandez A, et al. Acute, reversible pulmonary hypertension associated with cocaine use. Respir Med 1996; 90: 171-174.
22. Yakel DL Jr, Eisenberg MJ. Pulmonary artery hypertension in chronic intravenous cocaine users. Am Heart J 1995; 130: 398-399.
23. Schaiberger PH, Kennedy TC, Miller FC, et al. Pulmonary hypertension associated with long-term inhalation of "crank" methamphetamine. Chest 1993; 104: 614-616.
24. Chin KM, Channick RN, Rubin LJ. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest 2006; 130: 1657-1663.
25. Tseng YT, Padbury JF. Expression of a pulmonary endothelial norepinephrine transporter. J Neural Transm 1998; 105: 1187-1191.
26. Marcos E, Fadel E, Sanchez O, et al. Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res 2004; 94: 1263-1270.
27. Salvi SS. a1-adrenergic hypothesis for pulmonary hypertension. Chest 1999; 115: 1708-1719.
28. Wellman PJ, Maher TJ. Synergistic interactions between fenfluramine and phentermine. Int J Obes Relat Metab Disord 1999; 23: 723-732.
29. Rich S, Rubin L, Walker AM, et al. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest 2000; 117: 870-874.
30. Hagiwara M, Tsuchida A, Hyakkoku M, et al. Delayed onset of pulmonary hypertension associated with an appetite suppressant, mazindol: a case report. Jpn Circ J 2000; 64: 218-221.
31. Nittur N, Konofal E, Dauvilliers Y, et al. Mazindol in narcolepsy and idiopathic and symptomatic hypersomnia refractory to stimulants: a long-term chart review. Sleep Med 2013; 14: 30-36.
32. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
33. Ghofrani HA, Morrell NW, Hoeper MM, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010; 182: 1171-1177.
34. Rasheed W, Flaim B, Seymour JF. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 2009; 33: 861-864.
35. Mattei D, Feola M, Orzan F, et al. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant 2009; 43: 967-968.
36. Dumitrescu D, Seck C, ten Freyhaus H, et al. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J 2011; 38: 218-220.
37. Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125: 2128-2137.
38. Guignabert C, Montani D. Key roles of Src family tyrosine kinases in the integrity of the pulmonary vascular bed. Eur Respir J 2013; 41: 3-4.
39. Dusheiko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon-a: an economic appraisal. Hepatology 1995; 22: 1863-1873.
40. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. N Engl J Med 1989; 321: 1501-1506.
41. Brillanti S, Garson J, Foli M, et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994; 107: 812-817.
42. Anderson P, Höglund M, Rodjer S. Pulmonary side effects of interferon-alpha therapy in patients with hematological malignancies. Am J Hematol 2003; 73: 54-58.
43. Dhillon S, Kaker A, Dosanjh A, et al. Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C. Dig Dis Sci 2010; 55: 1785-1790.
44. Hanaoka M, Kubo K, Hayano T, et al. Interferon-alpha elevates pulmonary blood pressure in sheep-the role of thromboxane cascade. Eur J Pharmacol 1999; 370: 145-151.
45. Jochmann N, Kiecker F, Borges AC, et al. Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report. Cardiovasc Ultrasound 2005; 3: 26.
46. Caravita S, Secchi MB, Wu SC, et al. Sildenafil therapy for interferon-b-1a-induced pulmonary arterial hypertension: a case report. Cardiology 2011; 120: 187-189.
47. Ledinek AH, Jazbec SS, Drinovec I, et al. Pulmonary arterial hypertension associated with interferon beta treatment for multiple sclerosis: a case report. Multiple sclerosis 2009; 15: 885-886.
48. Humbert M, Simonneau G, Dinh-Xuan AT. Whistleblowers. Eur Respir J 2011; 38: 510-511.